Shantha’s Pentavalent Vaccine ‘Shan5’ launched in India

Shan5 is the first vaccine jointly developed by the Indian company and its parent company, Sanofi Pasteur

vaccine12332

(Photo Courtesy: www.frianyheter.nu)

Sanofi Pasteur, the vaccines division of Sanofi announced the launch of Shan5, its pediatric pentavalent vaccine developed and manufactured by its affiliate Shantha in India.

The launch of Shan5 vaccine received prequalification status from the World Health Organization (WHO) in April 2014.

Shan5's prequalification gives many more children in India access to the latest high-quality, fully-liquid, 5-in-1 vaccine.

Shan5 is a fully-liquid five-in-one, convenient, safe and high-quality vaccine that provides effective protection for children from 6 weeks of age against five diseases: diphtheria, tetanus, pertussis, Hib and hepatitis B. Shan5 vaccine has been developed and is produced by Shantha in Hyderabad, India.

Further, the prequalification helps Shan5 secure the supply of pentavalent combination vaccines in over 50 emerging and low-income countries.

 

Previous 1 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

GST

GST: Boon or Bane for Healthcare?

Send this article by email

X